Association of MRI features with IDH mutation status in patients with glioblastoma.

Association of MRI features with IDH mutation status in patients with glioblastoma. - MRI for IDH mutation in glioblastoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029521

Enrollment

450

Registered

2017-10-17

Start date

2017-10-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glioblastoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Glioblastoma confirmed by postoperative pathological exanination. 2. Preoperative MRI for glioblastoma. - T1WI - contrasted T1WI - transverse T2WI - FLAIR - DWI - DSC MR perfusion (if available) 3. IDH mutation tests of surgical specimen. 4. Twenty years or older at the time of preoperative MRI.

Exclusion criteria

Exclusion criteria: 1. Medication which affects MRI e.g. steroids. 2. Tissue type other than glioblastoma e.g. giant cell glioblastoma, gliosarcoma, epithelioid glioblastoma. 3. No transverse T2WI. 4. Not evaluable for artifacts. 5. Recurrence after treatment. 6. Judged ineligible by investigators.

Design outcomes

Primary

Measure	Time frame
tumor size, enhancement, non-enhanced region, necrosis size, edema size, location, ADC, rCBV.	—

Secondary

Measure	Time frame
subgroup analysis stratified by age, gender, etc.	—

Countries

Japan

Contacts

Public ContactToshinori Hirai

University of Miyazaki Department of Radiology, Faculty of Medicine

toshinorh@med.miyazaki-u.ac.jp0985-85-2807

Outcome results